365 related articles for article (PubMed ID: 17027743)
1. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
[TBL] [Abstract][Full Text] [Related]
2. A simple and powerful flow cytometric method for the simultaneous determination of multiple parameters at G protein-coupled receptor subtypes.
Schneider E; Mayer M; Ziemek R; Li L; Hutzler C; Bernhardt G; Buschauer A
Chembiochem; 2006 Sep; 7(9):1400-9. PubMed ID: 16888730
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
4. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
Dautzenberg FM; Neysari S
Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
[TBL] [Abstract][Full Text] [Related]
5. Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions.
Akerberg H; Fällmar H; Sjödin P; Boukharta L; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Regul Pept; 2010 Aug; 163(1-3):120-9. PubMed ID: 20471432
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of neuropeptide Y-mediated calcium responses in human SMS-KAN neuroblastoma cells endogenously expressing Y2 receptors by co-expression of chimeric G proteins.
Dautzenberg FM
Biochem Pharmacol; 2005 May; 69(10):1493-9. PubMed ID: 15857613
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y as a partial agonist of the Y1 receptor.
Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL
Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244
[TBL] [Abstract][Full Text] [Related]
8. Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence.
Ziemek R; Schneider E; Kraus A; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
J Recept Signal Transduct Res; 2007; 27(4):217-33. PubMed ID: 17885919
[TBL] [Abstract][Full Text] [Related]
9. Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology.
Mellentin-Michelotti J; Evangelista LT; Swartzman EE; Miraglia SJ; Werner WE; Yuan PM
Anal Biochem; 1999 Aug; 272(2):182-90. PubMed ID: 10415087
[TBL] [Abstract][Full Text] [Related]
10. Pertussis toxin induces parallel loss of neuropeptide Y Y1 receptor dimers and Gi alpha subunit function in CHO cells.
Parker SL; Parker MS; Sah R; Balasubramaniam A; Sallee FR
Eur J Pharmacol; 2008 Jan; 579(1-3):13-25. PubMed ID: 17967449
[TBL] [Abstract][Full Text] [Related]
11. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
[TBL] [Abstract][Full Text] [Related]
14. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.
Doods H; Gaida W; Wieland HA; Dollinger H; Schnorrenberg G; Esser F; Engel W; Eberlein W; Rudolf K
Eur J Pharmacol; 1999 Nov; 384(2-3):R3-5. PubMed ID: 10611450
[TBL] [Abstract][Full Text] [Related]
15. Towards understanding the free and receptor bound conformation of neuropeptide Y by fluorescence resonance energy transfer studies.
Haack M; Beck-Sickinger AG
Chem Biol Drug Des; 2009 Jun; 73(6):573-83. PubMed ID: 19635049
[TBL] [Abstract][Full Text] [Related]
16. Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist.
Dautzenberg FM; Higelin J; Pflieger P; Neidhart W; Guba W
Neuropharmacology; 2005 Jun; 48(7):1043-55. PubMed ID: 15857631
[TBL] [Abstract][Full Text] [Related]
17. A fluorescent reporter assay for the detection of ligands acting through Gi protein-coupled receptors.
Xing H; Tran HC; Knapp TE; Negulescu PA; Pollok BA
J Recept Signal Transduct Res; 2000 Nov; 20(4):189-210. PubMed ID: 11192018
[TBL] [Abstract][Full Text] [Related]
18. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo.
Malmström RE; Lundberg JN; Weitzberg E
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):106-11. PubMed ID: 11819028
[TBL] [Abstract][Full Text] [Related]
19. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
Keller M; Teng S; Bernhardt G; Buschauer A
ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors.
Körner M; Reubi JC
J Neuropathol Exp Neurol; 2008 Aug; 67(8):741-9. PubMed ID: 18648328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
